Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 15/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040070 | 0.71 | SLC29A1 (0.72) | SLC29A1 | |
| SCHEMBL5040813 | 0.69 | SLC29A1 (0.77) | SLC29A1 | |
| SCHEMBL5037582 | 0.69 | CYP1A2 (0.50) | CYP1A2TSHRADORA2ASLC29A1 | |
| SCHEMBL5040197 | 0.69 | CYP1A2 (0.52) | CYP1A2TSHRADORA2ASLC29A1 | |
| SCHEMBL14203575 | 0.68 | SLC29A1 (0.40) | CYP1A2ADORA2ASLC29A1ADORA1 | |
| SCHEMBL14203634 | 0.67 | CYP1A2 (0.44) | CYP1A2SLC29A1 | |
| SCHEMBL8982987 | 0.66 | ADORA2A (0.68) | CYP1A2TSHRADORA2AADORA2BADORA1 | |
| SCHEMBL31331791 | 0.66 | ADORA2A (0.68) | CYP1A2TSHRADORA2AADORA2BADORA1 | |
| SCHEMBL5042019 | 0.65 | CYP1A2 (0.50) | CYP1A2TSHRADORA2ASLC29A1ADORA2B | |
| SCHEMBL5042020 | 0.65 | CYP1A2 (0.49) | CYP1A2TSHRADORA2ASLC29A1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492803-B1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | GRUENENTHAL GMBH (DE) | 2008-06-11 | — | — | EP | claimed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | claimed |
| JP-2005526106-A | — | — | 2005-09-02 | — | — | JP | claimed |
| US-20050096293-A1 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | claimed |
| EP-1492803-A1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003084975-A1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2003-10-16 | — | — | WO | claimed |
| EP-1352910-A1 | New analogs of nitrobenzylthioinosine | Grünenthal GmbH (DE) | 2003-10-15 | — | — | EP | claimed |
| EP-1492803-B1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | GRUENENTHAL GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1492803-B1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | GRUENENTHAL GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-20050096293-A1 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
| EP-1492803-A1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084975-A1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2003-10-16 | — | — | WO | disclosed |
| EP-1352910-A1 | New analogs of nitrobenzylthioinosine | Grünenthal GmbH (DE) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096293-A1 | Analogs of nitrobenzylthioinosine | NUDT1, TYMP, NNMT | CYP1A2 2256/4885TSHR 2011/4885ADORA2A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.